Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Timing of Adverse Events During Maintenance Treatment with Rucaparib for Recurrent Ovarian Cancer in Phase 3 Study

Conference Correspondent  - ESMO Highlights

ARIEL3 is a randomized, double-blind, placebo-controlled, phase 3 study investigating the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib as maintenance therapy versus placebo in patients with recurrent ovarian cancer regardless of biomarker status. The patients were randomized 2:1 to receive rucaparib 600 mg twice daily (n = 372) or placebo (n = 189) until disease progression or treatment discontinuation due to toxicity or other reasons. Safety was monitored for all patients who received at least 1 dose of rucaparib.

The median duration of treatment was 8.3 months (range, 0-67 months) for patients taking rucaparib and 5.5 months (range, 0-68 months) for those taking placebo. In the rucaparib arm, 62.1% (372) of patients experienced at least 1 treatment-emergent adverse event (TEAE) of grade ≥3, while in the placebo arm, only 16.4% (31) of patients experienced a TEAE. Discontinuation due to TEAEs (separate from discontinuation due to disease progression) occurred in 17.2% of patients in the rucaparib study arm, and in 1.6% of patients in the placebo arm. The most commonly reported TEAE (any grade) was nausea, which occurred in 76.3% of patients receiving rucaparib treatment and 37.0% of patients receiving placebo. Median time to first onset of nausea was 5 days (95% confidence interval [CI], 4-6) in the rucaparib arm and 17 days (95% CI, 7-57) in the placebo arm. Nausea was mostly grade 1 and was more common at the beginning of rucaparib treatment, declining from 66.9% in month 1 to 22.2% in month 24.

Asthenia/fatigue occurred in 71.8% of patients receiving rucaparib and 45.0% of patients taking placebo. Median time to first onset of asthenia/fatigue was 15 days (95% CI, 15-20) for rucaparib and 30 days (95% CI, 16-37) for placebo. Dysgeusia occurred in 39.8% of patients on rucaparib and 6.9% of patients receiving placebo. Median time of onset was 10 days (95% CI, 6-15) with rucaparib and 11 days (95% CI, 3-29) with placebo. The incidence of anemia/decreased hemoglobin was 39.5% with rucaparib and 4.8% with placebo. Median time of onset was 67 days (95% CI, 57-85) with rucaparib and 54 days (95% CI, 15-140) with placebo. Constipation was experienced by 37.9% of patients taking rucaparib and 23.3% of patients taking placebo. Median time of onset was 40 days (95% CI, 29-55) with rucaparib and 46 days (95% CI, 23-81) with placebo. Vomiting was experienced by 37.4% of patients taking rucaparib and 15.3% of patients taking placebo. Median time of onset for patients experiencing vomiting was 24 days (95% CI, 15-39) for rucaparib patients and 84 days (95% CI, 36-129) for patients taking placebo.

For the majority of frequently reported TEAEs of any grade, the median time to onset was ≤45 days and the mean duration of the first event was generally <60 days, with some TEAEs having first-onset times >45 days (anemia/decreased hemoglobin, abdominal pain, neutropenia/decreased neutrophils) or durations of approximately 90 to 160 days (asthenia/fatigue, decreased appetite, dysgeusia).

Reference

Abstract and Poster 821P. ESMO 2020. September 19-21, 2020. Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study.

Related Items
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Web Exclusives published on November 3, 2020 in ESMO Highlights
Trabectedin/PLD versus Carboplatin/PLD in Recurrent Ovarian Cancer Progressing within 6-12 Months After Last Platinum Line
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Safety and Efficacy of XMT-1536 in Ovarian Cancer: Subgroup Analysis from a Phase 1 Expansion Study
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Maintenance Olaparib plus Bevacizumab for Newly Diagnosed High-Grade Ovarian Cancer: Second Progression-Free Survival
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Real-World Data on Platinum Therapy in High-Grade Serous Ovarian Cancer Patients Progressing After PARP Inhibitor Treatment
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Atezolizumab in Patients with Newly Diagnosed Stage III or Stage IV Ovarian Cancer
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Mirvetuximab Soravtansine in Combination with Carboplatin and Bevacizumab in Recurrent Ovarian Cancer
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Patient-Reported Outcomes in Patients Receiving Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Nivolumab versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients with Platinum-Resistant Ovarian Cancer: The NINJA Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Individualized Starting Dose of Niraparib to Treat Platinum-Sensitive Recurrent Ovarian Cancer: The NORA Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.